+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 120Years
All Genders
ID04847063

Evaluating Individualized Responses to Heated Abdominal Chemotherapy Using Cytoreductive Surgery for Peritoneal Carcinomatosis From Mesothelioma, Ovarian, Colorectal, or Appendiceal Cancer

Led by National Cancer Institute (NCI) · Updated on 2026-11-03

60

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying peritoneal carcinomatosis, a condition where tumors have spread to the lining of the abdomen from cancers such as peritoneal mesothelioma, ovarian, colorectal, appendiceal, or atypical mesothelial proliferation. This study aims to improve the effectiveness of cytoreductive surgery CRS combined with hyperthermic intraperitoneal chemotherapy HIPEC by using innovative models to test different chemotherapy drugs on removed tumor tissue versus tumors treated inside the body before removal. Participants will undergo cytoreductive surgery to remove as many visible tumors as possible, leaving a few tumors to receive HIPEC treatment during surgery. Four different HIPEC chemotherapy regimens are studied, with drugs including oxaliplatin with 5-fluorouracil, mitomycin C, and combinations of cisplatin with doxorubicin or mitomycin C plus intravenous sodium thiosulfate to reduce side effects. Tumor tissue samples are tested with the SMART System or 3-D cell culture models to simulate HIPEC treatment outside the body. During the study, participants will provide various biological samples, such as tumor tissue, fluids, blood, saliva, cheek swabs, and stool for research. They will complete health and quality of life surveys and may undergo genetic testing if they have peritoneal mesothelioma. Follow-up visits will occur for up to five years after surgery to monitor health and disease progression. If the disease worsens, participants may undergo CRS with HIPEC again, followed by further monitoring.

CONDITIONS

Brief Title

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Research Team

S

Stephanie N Canady, R.N.

A

Andrew M Blakely, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here